Scrip Asks…What Does 2022 Hold For Biopharma? Part 2: Deal Making, M&A And Financial Markets

More M&A Expected As Biotech Valuations Decline

Following two record-breaking years for biotech fundraising, stock valuations are heading downwards. Biopharma executives and industry experts surveyed by Scrip anticipate big pharma executing more deals and acquisitions in 2022.

Scrip Asks, Part 2
• Source: Alamy

As Stephen Rosen, head of the corporate practice in London at law firm Cooley observed, “We start 2022 in the rare position of the sector never having as high a profile amongst investors [as] it does today. There are more investors looking to invest in the biotech sector, and as we have seen larger funds raised over the last few years, so the ability to deploy significant funds, particularly with the tranched funding that is a frequent theme for companies in the sector, means that interest and therefore M&A opportunities are likely to continue.”

Nevertheless, the bullish atmosphere that surrounded biotech stocks in 2020 and the first part of 2021 turned in September 2021,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Scrip Asks

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.